Leukotriene C4 synthase: Upcoming drug target for inflammation

Current Drug Targets

Volumn 13, Issue 8, 2012, Pages 1107-1118

  Devi, Nisha S ^a   Doble, Mukesh ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY MADRAS   (India)

Author keywords

Anti inflammatory drugs; Asthma; Inflammation; Inhibitors; Leukotriene C4 synthase

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; BISAROMATIC; BISARYL; DIETHYLCARBAMAZINE; HELENALIN; INDOLE DERIVATIVE; LEUKOTRIENE C4 SYNTHASE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHYLENE BSIPHENYL; N ETHYLMALEIMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; THYMOQUINONE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CRYSTAL STRUCTURE; DRUG TARGETING; HUMAN; IN VIVO STUDY; INFLAMMATION; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ENZYME INHIBITORS; GLUTATHIONE TRANSFERASE; HUMANS; INFLAMMATION; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84863541853     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: None     Document Type: Article

References (109)

1. Davies P, Bailey PJ, Goldenberg MM, Ford-Hutchinson AW. The role of arachidonic acid oxygenation products in pain and inflammation. Annu Rev Immunol 1984; 2(1): 335-57.
2. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001; 294(5548): 1871.
3. Levy B. Lipoxins and lipoxin analogs in asthma. Prostaglands Leukot Essent Fatty Acids 2005; 73(3-4): 231-7.
4. Sharma J, Mohammed L. The role of leukotrienes in the pathophysiology of inflammatory disorders: is there a case for revisiting leukotrienes as therapeutic targets? Inflammopharmacology 2006; 14(1): 10-6.
5. Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 2001; 108(1): 15-24.
6. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983; 220(4597): 568.
7. Gillard J, Ford-Hutchinson A, Chan C, et al. L-663,536 (MK- 886)(3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2, 2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharm 1989; 67(5): 456-64.
8. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999; 340(3): 197-206.
9. Manning PJ, Watson RM, Margolskee DJ, Williams VC, Schwartz JI, O'Byrne PM. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N Engl J Med 1990; 323(25): 1736-9.
10. Wahedna I, Wisniewski A, Tattersfield A. Effect of RG 12525, an oral leukotriene D4 antagonist, on the airway response to inhaled leukotriene D4 in subjects with mild asthma. Br J Clin Pharmacol 1991; 32(4): 512.
11. Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotrienereceptor antagonist, for the treatment of mild asthma and exerciseinduced bronchoconstriction. N Engl J Med 1998; 339(3): 147-52.
12. Lam BK, Frank Austen K. Leukotriene C4 synthase. A pivotal enzyme in the biosynthesis of the cysteinyl leukotrienes. Am J Resp Crit Care 2000; 161(2): S16.
13. Penrose JF, Gagnon L, Goppelt-Struebe M, et al. Purification of human leukotriene C4 synthase. P Natl Acad Sci USA 1992; 89(23): 11603.
14. Gupta N, Gresser MJ, Ford-Hutchinson AW. Kinetic mechanism of glutathione conjugation to leukotriene A4 by leukotriene C4 synthase. Biochim Biophys Acta 1998; 1391(2): 157-68.
15. Murphy RC, Hammarström S, Samuelsson B. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci USA 1979; 76(9): 4275.
16. HayTheodore J, Douglas W. Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Trends Pharmacol Sci 1995; 16(9): 304-9.
17. McGeehan M, Bush R. The mechanisms of aspirin-intolerant asthma and its management. Curr Allergy Asthma Rep 2002; 2(2): 117-25.
18. Adamjee J, Suh Y. Expression of 5-lipoxygenase and cyclooxygenase pathway enzymes in nasal polyps of patients with aspirin-intolerant asthma. J Pathol 2006; 209(3): 392-9.
19. Amat M, Barcons M, Mancebo J, et al. Evolution of leukotriene B4, peptide leukotrienes, and interleukin-8 plasma concentrations in patients at risk of acute respiratory distress syndrome and with acute respiratory distress syndrome: mortality prognostic study. Crit Care Med 2000; 28(1): 57.
20. Matthay MA, Eschenbacher WL, Goetzl EJ. Elevated concentrations of leukotriene D 4 in pulmonary edema fluid of patients with the adult respiratory distress syndrome. J Clin Immunol 1984; 4(6): 479-83.
21. Petric R, Ford-Hutchinson A. Inhibition of leukotriene biosynthesis improves renal function in experimental glomerulonephritis. J Lipid Mediat 1995; 11(3): 231-40.
22. Al-Amran F, Hadi N, Hashim A. Leukotriene biosynthesis inhibition ameliorates acute lung injury following hemorrhagic shock in rats. J Cardiothorac Surg 2011; 6(1): 81.
23. Schröder O, Sjöström M, Qiu H, Jakobsson PJ, Haeggström J. Microsomal glutathione S-transferases: selective up-regulation of leukotriene C 4 synthase during lipopolysaccharide-induced pyresis. Cell Mol Life Sci 2005; 62(1): 87-94.
24. Kanaoka Y, Maekawa A, Penrose JF, Austen KF, Lam BK. Attenuated zymosan-induced peritoneal vascular permeability and IgE-dependent passive cutaneous anaphylaxis in mice lacking leukotriene C4 synthase. J Biol Chem 2001; 276(25): 22608.
25. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase. JAMA-J Am Med Assoc 2006; 296(13): 1633.
26. Rao NL, Dunford PJ, Xue X, et al. Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton. J Pharmacol Exp Ther 2007; 321(3): 1154.
27. Hui Y, Funk CD. Cysteinyl leukotriene receptors. Biochem Pharmacol 2002; 64(11): 1549-57.
28. Lynch KR, O'Neill GP, Liu Q, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 1999; 399(6738): 789-93.
29. Heise CE, O'Dowd BF, Figueroa DJ, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 2000; 275(39): 30531.
30. Haeggstrom JZ, Funk CD. Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chem Rev 2011; 111(10): 5866-98
31. Haeggström JZ, Rinaldo-Matthis A, Wheelock CE, Wetterholm A. Advances in eicosanoid research, novel therapeutic implications. Biochem Biophys Res Commun 2010; 396(1): 135-9.
32. Lam BK. Leukotriene C4 synthase. Prostaglands Leukot Essent Fatty Acid 2003; 69(2-3): 111-6.
33. Maclouf J, Murphy RC. Transcellular metabolism of neutrophilderived leukotriene A4 by human platelets. A potential cellular source of leukotriene C4. J Biol Chem 1988; 263(1): 174.
34. Tornhamre S, Sjölinder M, Lindberg Å, et al. Demonstration of leukotriene C4 synthase in platelets and species distribution of the enzyme activity. Eur J Biochem 1998; 251(1-2): 227-35.
35. Edenius C, Heidvall K, Lindgren JÅ. Novel transcellular interaction: conversion of granulocyte-derived leukotriene A4 to cysteinyl-containing leukotrienes by human platelets. Eur J Biochem 1988; 178(1): 81-6.
36. Henderson Jr WR, Tang Liou, Chu SJ, et al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respr Crit Care 2002; 165(1): 108.
37. Holgate ST, Peters-Golden M, Panettieri RA, Henderson WR. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J Allergy Clin Immun 2003; 111(1): S18-S36.
38. Takasaki J, Kamohara M, Matsumoto M, et al. The Molecular Characterization and Tissue Distribution of the Human Cysteinyl Leukotriene CysLT2 Receptor. Biochem Biophys Res Commun 2000; 274(2): 316-22.
39. Zaitsu M, Hamasaki Y, Matsuo M, Ichimaru T, Fujita I, Ishii E. Leukotriene synthesis is increased by transcriptional up-regulation of 5-lipoxygenase, leukotriene A4 hydrolase, and leukotriene C4 synthase in asthmatic children. J Asthma 2003; 40(2): 147-54.
40. Coffey M, Peters-Golden M. Extending the understanding of leukotrienes in asthma. Curr Opin Allergy Clin Immunol 2003; 3(1): 57.
41. Nakajima T, Asano K. Aspirin-induced asthma. Allergy Pract 2004; 313: 23-7.
42. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immun 1999; 104(1): 5-13.
43. Babu KS, Salvi SS. Aspirin and Asthma. Chest 2000; 118(5): 1470.
44. Sanak M, Simon HU, Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997; 350(9091): 1599.
45. Sayers I, Barton S, Rorke S, et al. Allelic association and functional studies of promoter polymorphism in the leukotriene C4 synthase gene (LTC4S) in asthma. Thorax 2003; 58(5): 417.
46. Sjölinder M, Stenke L, Näsman-Glaser B, et al. Aberrant expression of active leukotriene C4 synthase in CD16+ neutrophils from patients with chronic myeloid leukemia. Blood 2000; 95(4): 1456.
47. Shakoory B, Fitzgerald SM, Lee SA, Chi DS, Krishnaswamy G. The role of human mast cell-derived cytokines in eosinophil biology. J Interferon Cytokine Res 2004; 24(5): 271-81.
48. Hirata H, Arima M, Fukushima Y, et al. Over-expression of the LTC4 synthase gene in mice reproduces human aspirin-induced asthma. Clin Exp Allergy 2011; 41: 1133-42.
49. Peters-Golden M, Henderson Jr WR. Leukotrienes. N Engl J Med 2007; 357(18): 1841-54.
50. Riddick CA, Serio KJ, Hodulik CR, Ring WL, Regan MS, Bigby TD. TGF-ß Increases Leukotriene C4 Synthase Expression in the Monocyte-Like Cell Line, THP-1. J Immunol 1999; 162(2): 1101.
51. Murakami M, Austen KF, Bingham CO, Friend DS, Penrose JF, Arm JP. Interleukin-3 regulates development of the 5- lipoxygenase/leukotriene C4 synthase pathway in mouse mast cells. J Biol Chem 1995; 270(39): 22653.
52. Saino H, Ukita Y, Ago H, et al. The catalytic architecture of Leukotriene C4 Synthase with two arginine residues. J Biol Chem 2011; 286(18): 16392.
53. Ago H, Kanaoka Y, Irikura D, et al. Crystal structure of a human membrane protein involved in cysteinyl leukotriene biosynthesis. Nature 2007; 448(7153): 609-12.
54. Rinaldo-Matthis A, Wetterholm A, Molina DM, et al. Arginine 104 is a key catalytic residue in leukotriene C4 synthase. J Biol Chem 2010; 285(52): 40771.
55. Molina DM, Wetterholm A, Kohl A, et al. Structural basis for synthesis of inflammatory mediators by human leukotriene C4 synthase. Nature 2007; 448(7153): 613-6.
56. Schmidt-Krey I, Kanaoka Y, Mills DJ, et al. Human leukotriene C4 synthase at 4.5 Å resolution in projection. Structure 2004; 12(11): 2009-14.
57. Saino H, Ago H, Ukita Y, Miyano M. Seleno-detergent MAD phasing of leukotriene C4 synthase in complex with dodecyl--Dselenomaltoside. Acta Crystallogr Sect F Struct Biol Cryst Commun 2011; 67(12): 1666-73.
58. Jakobsson PJ, Morgenstern R, Mancini J, Ford-Hutchinson A, Persson B. Membrane-associated proteins in eicosanoid and glutathione metabolism (MAPEG). A widespread protein superfamily. Am J Resp Crit Care 2000; 161(2): S20.
59. Jakobsson PJ, Morgenstern R, Mancini J, Ford-Hutchinson A, Persson B. Common structural features of MAPEG-a widespread superfamily of membrane associated proteins with highly divergent functions in eicosanoid and glutathione metabolism. Protein Sci 1999; 8(3): 689-92.
60. Bresell A, Weinander R, Lundqvist G, et al. Bioinformatic and enzymatic characterization of the MAPEG superfamily. FEBS J 2005; 272(7): 1688-703.
61. Martinez Molina D, Eshaghi S, Nordlund P. Catalysis within the lipid bilayer--structure and mechanism of the MAPEG family of integral membrane proteins. Curr Opin Struc Biol 2008; 18(4): 442-9.
62. Haeggstrom JZ, Rinaldo-Matthis A, Wheelock CE, Wetterholm A. Advances in eicosanoid research, novel therapeutic implications. Biochem Biophys Res Commun 2010; 396(1): 135-9.
63. Zimmer JSD, Voelker DR, Bernlohr DA, Murphy RC. Stabilization of leukotriene A4 by epithelial fatty acid-binding protein in the rat basophilic leukemia cell. J Biol Chem 2004; 279(9): 7420.
64. Früh V, Zhou Y, Chen D, et al. Application of fragment-based drug discovery to membrane proteins: identification of ligands of the integral membrane enzyme DsbB. Chem Biol 2010; 17(8): 881-91.
65. Lyss G, Knorre A, Schmidt TJ, Pahl HL, Merfort I. The antiinflammatory sesquiterpene lactone helenalin inhibits the transcription factor NFκB by directly targeting p65. J Biol Chem 1998; 273(50): 33508.
66. Tornhamre S, Schmidt TJ, Näsman-Glaser B, Ericsson I, Lindgren JÅ. Inhibitory effects of helenalin and related compounds on 5- lipoxygenase and leukotriene C4 synthase in human blood cells. Biochem Pharmacol 2001; 62(7): 903-11.
67. El Gazzar M, El Mezayen R, Marecki JC, Nicolls MR, Canastar A, Dreskin SC. Anti-inflammatory effect of thymoquinone in a mouse model of allergic lung inflammation. Int Immunopharmacol 2006; 6(7): 1135-42.
68. Mansour M, Tornhamre S. Inhibition of 5-lipoxygenase and leukotriene C4 synthase in human blood cells by thymoquinone. J Enzyme Inhib Med Chem 2004; 19(5): 431-6.
69. El Gazzar M, El Mezayen R, Nicolls MR, Marecki JC, Dreskin SC. Downregulation of leukotriene biosynthesis by thymoquinone attenuates airway inflammation in a mouse model of allergic asthma. Biochim Biophys Acta 2006; 1760(7): 1088-95.
70. Lam BK, Penrose JF, Freeman GJ, Austen KF. Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4. P NatlAcad Sci USA 1994; 91(16): 7663.
71. Sala A, Folco G, Henson PM, Murphy RC. Pharmacological modulation of human platelet leukotriene C4-synthase. Biochem Pharmacol 1997; 53(6): 905-8.
72. Nicholson DW, Ali A, Klemba M, Munday N, Zamboni R, Ford-Hutchinson A. Human leukotriene C4 synthase expression in dimethyl sulfoxide-differentiated U937 cells. J Biol Chem 1992; 267(25): 17849.
73. Hutchinson JH, Charleson S, Evans JF, et al. Thiopyranol [2, 3, 4- c, d] indoles as inhibitors of 5-lipoxygenase, 5-lipoxygenaseactivating protein, and leukotriene C4 synthase. J Med Chem 1995; 38(22): 4538-47.
74. Nilsson P, Katkevics M, Pelcman B. Bis-Aryl compounds for use as medicaments. United States Patent Application 20110112193 A1, May 12, 2011.
75. Nilsson P, Pelcman B, Katkevics M. Bis aromatic compounds for use as LTC4 synthase inhibitors. International Publication Number WO/2010/103283 A1; Sep 16, 2010.
76. Nilsson P. Indoles useful in the treatment of inflammation. International Publication Number WO/2010/076566 A2; Jul 8, 2010.
77. Pelcman B, Nilsson P. New Methylenebisphenyl Compounds Useful in the Treatment of Inflammation. International Publication Number WO/2008/107661 A1; Sep 12, 2008.
78. Watanabe T, Suzuki T, Umezawa Y, Takeuchia T, Otsukac M, Umezawab K. Structure-Activity Relationship and Rational Design of 3,4-Dephostatin Derivatives as Protein Tyrosine Phosphatase Inhibitors. Tetrahedron 2000; 56(5): 741-752.
79. Stouch TR, Gudmundsson O. Progress in understanding the structure-activity relationships of P-glycoprotein. Adv Drug Deliv Rev 2002; 54(3): 315-28.
80. Hambley TW. The influence of structure on the activity and toxicity of Pt anti-cancer drugs. Coord Chem Rev 1997; 166: 181-223.
81. Domagala JM. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother 1994; 33(4): 685.
82. Seyhan N. Organic Chemistry 2nd ed. USA: DC Health and Company 1989.
83. Acheson RM. An introduction to the chemistry of heterocyclic compounds, NY: USA. John Wiley & Sons Ltd 1976.
84. Weissberger A. Chemistry of heterocyclic compounds. NY: Wiley- Interscience 1961.
85. Sumpter WC, Miller FM. Heterocyclic compounds with indole and carbazole systems. NY: Interscience publishers 1954.
86. Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 2002; 1(2): 153-62.
87. Walters WP, Murcko AA, Murcko MA. Recognizing molecules with drug-like properties. Curr Opin Chem Biol 1999; 3(4): 384-7.
88. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol 2000;44(1): 235-49.
89. Di L, Kerns EH. Profiling drug-like properties in discovery research. Curr Opin Chem Biol 2003; 7(3): 402-8.
90. Kerns EH, Di L. Drug-like properties: concepts, structure design and methods: from ADME to toxicity optimization. Academic Press: New York 2008.
91. Lee KH, Meck R, Piantadosi C, Huang ES. Antitumor agents. 4. Cytotoxicity and in vivo activity of helenalin esters and related derivatives. J Med Chem 1973; 16(3): 299-301.
92. Chapman DE, Roberts G, Reynolds D, et al. Acute toxicity of helenalin in BDF1 mice. Fund Appl Toxicol 1988; 10(2): 302-12.
93. Schmidt TJ. Glutathione adducts of helenalin and 11 alpha, 13- dihyrohelenalin acetate inhibit glutathione S-transferase from horse liver. Planta Med 2000; 66: 106-9.
94. Beekman AC, Woerdenbag HJ, van Uden W, et al. Structurecytotoxicity relationships of some helenanolide-type sesquiterpene lactones. J Nat Prod 1997; 60(3): 252-7.
95. Schmidt TJ. Helenanolide-type sesquiterpene lactones--III. Rates and stereochemistry in the reaction of helenalin and related helenanolides with sulfhydryl containing biomolecules. Bioorgan Med Chem 1997; 5(4): 645-53.
96. Woynarowski Janm, Konopa J. Inhibition of DNA biosynthesis in HeLa cells by cytotoxic and antitumor sesquiterpene lactones. Mol Pharmacol 1981; 19(1): 97.
97. Grippo AA, Wyrick SD, Lee KH, Shrewsbury RP, Hall IH. Disposition of an antineoplastic sesquiterpene lactone,[3H]- plenolin, in BDF1 mice. Planta med 1991; 57(4): 309-14.
98. Nasaruddin Nbin. Extraction of pharmacologically active thymoquinone in nigella sativa L. EngD Thesis. Malaysia: University College of Engineering and Technology November 2006.
99. Wei M, Xu S, Lam AC. Increased amorphous stability of poorly water soluble drugs by nanosizing. US Patent App. 2008/0181,957, Jun 22, 2007.
100. Ganea GM, Fakayode SO, Losso JN, van Nostrum CF, Sabliov CM, Warner IM. Delivery of phytochemical thymoquinone using molecular micelle modified poly (D, L lactide-coglycolide)(PLGA) nanoparticles. Nanotechnology 2010; 21: 285104.
101. Lupidi G, Scire A, Camaioni E, et al. Thymoquinone, a potential therapeutic agent of Nigella sativa, binds to site I of human serum albumin. Phytomedicine 2010; 17(10): 714-20.
102. Al-Amri AM, Bamosa AO. Phase I Safety and clinical activity study of thymoquinone in patients with advanced refractory malignant disease. SEMJ 2009; 10(3): 107-11.
103. Gugliucci A, Ranzato L, Scorrano L, et al. Mitochondria are direct targets of the lipoxygenase inhibitor MK886. J Biol Chem 2002;277(35): 31789.
104. Steinhilber D. 5-Lipoxygenase: a target for antiinflammatory drugs revisited. Curr Med Chem 1999; 6(1): 71-86.
105. Gregory JD. The stability of N-ethylmaleimide and its reaction with sulfhydryl groups. J Am Chem Soc 1955; 77(14): 3922-3.
106. Han A, Sinclair WK, Kimler BF. The effect of N-ethylmaleimide on the response to X rays of synchronized HeLa cells. Radiat Res 1976; 65(2): 337-50.
107. Izumi T, Honda Z, Ohishi N, et al. Solubilization and partial purification of leukotriene C4 synthase from guinea-pig lung: a microsomal enzyme with high specificity towards 5, 6-epoxide leukotriene A4. Biochim Biophys Acta 1988; 959(3): 305.
108. Welsch DJ, Creely DP, Hauser SD, Mathis KJ, Krivi GG, Isakson PC. Molecular cloning and expression of human leukotriene-C4 synthase. Proc Natl Acad Sci USA 1994; 91(21): 9745.
109. Lam BK, Penrose JF, Rokach J, Xu K, Baldasaro MH, Austen KF. Molecular cloning, expression and characterization of mouse leukotriene C4 synthase. Eur J Biochem 1996; 238(3): 606-12.